Interview with ATRIVA CEO during BIO-Europe Spring(R) 2017

During the BIO-Europe Spring (R) event 2017, ATRIVA's CEO Dr. Rainer Lichtenberger was interviewed about the aims and future of ATRIVA.

You can watch the video on the newspage by clicking on it!

 

New paper published about anti-influenza activity of CI-1040

Our scientific founders published a new paper on antiviral action of MEK inhbitors in Antiviral Research, the highest-ranking journal in the area of antiviral therapy and the fourth-highest in the general field of virology.

Weiterlesen

Host with the most: Targeting host cells instead of pathogens to fight infectious disease

In a recent news article published in Nature Medicine by Amanda B. Keener, the background of Atriva's antiviral MEK inhibitor technology was highlighted. Three of our founders were interviewed in this article and shared their views on past and future developments in influenza treatment:

Nature Medicine 23, 528–531 doi:10.1038/nm0517-528

Atriva receives seed financing to develop its next generation influenza therapeutic

The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

Weiterlesen

Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

Tübingen, Germany, November 04, 2016 -- Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the treatment of virus diseases” (US Application 14/434,328) is intended.

Weiterlesen